Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Use of Personalized Medicine to Select Adjuvant Breast Cancer Therapy

April 17th 2013

Clinical trials are under way that may change the way risk of recurrence is assessed for early-stage breast cancer patients, allowing for individualization of therapy.

Managing Menopausal Symptoms in Breast Cancer Patients

April 16th 2013

J. Michael Dixon, MD, describes a number of effective options for clinicians to help patients better manage menopausal symptoms in patients with breast cancer and improve their quality of life.

Emanuel Petricoin Describes Screening With Biomarkers

April 16th 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.

Framing the Mastectomy Debate-The Trends

April 15th 2013

A review of several studies examining the long-term benefits of breast-conservation therapy compared with mastectomy for women with stage breast cancer.

Dr. Sledge Defines the Term "Smart" Cancer

April 15th 2013

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, defines a "smart" cancer.

Dr. Tripathy on Maintenance Therapy in Breast Cancer

April 12th 2013

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses maintenance therapy for patients with breast cancer.

Embracing a Challenge: Breast Cancer Expert Pushes Forward After Much Success

April 12th 2013

An interview with José Baselga, MD, PhD, who helped to develop new drugs and combination therapies for the treatment of breast cancer, including the early targeted therapy trastuzumab and the more recent pertuzumab.

Dr. Piccart Explains the Benefit of the IMPAKT Conference

April 11th 2013

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an overview of the IMPAKT conference.

Palbociclib Receives Breakthrough Designation for Treatment of Breast Cancer

April 10th 2013

The drug palbociclib (formerly known as PD-0332991) has received has received a "breakthrough therapy designation" from the FDA for the treatment of patients with breast cancer.

Dr. Esserman on the I-SPY 2 Trial in Breast Cancer

April 10th 2013

Laura Esserman, MD, MBA, Professor, University of California, San Francisco, comments on the findings from the I-SPY 1 trial and the basis for the I-SPY 2 trial in patients with breast cancer.

Baselga Recaps Research Into Three Breast Cancer Pathways

April 9th 2013

José Baselga, MD, PhD, explores the dual inhibition of cell-signaling pathways in breast cancer on several fronts, including new therapies for patients with the HER2-positive subtype and novel ways to target mTOR and the PI3K/Akt/mTOR pathway.

Dr. Borgen Discusses the Patents on BRCA1 and BRCA2

April 8th 2013

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the patents on BRCA1 and BRCA2.

Dr. Carey on Everolimus in Metastatic Breast Cancer

April 5th 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the use of everolimus in the metastatic and adjuvant settings of breast cancer.

Dr. Sledge Discusses Lasting Issues in Breast Cancer

April 4th 2013

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the lasting issues in the treatment of breast cancer.

Dr. Muss on the Treatment Team for Older Cancer Patients

April 3rd 2013

Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine, discusses the need for a team environment when treating an older patient.

Dr. Andre on Research in Metastatic Breast Cancer

April 2nd 2013

Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche Médicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, discusses upcoming research in metastatic breast cancer.

Dr. Baselga Discusses PIK3CA Inhibitors in Breast Cancer

March 29th 2013

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses treatment with PIK3CA inhibitors in patients with breast cancer.

Emanuel Petricoin Discusses Tumor Heterogeneity

March 28th 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses tumor heterogeneity in patients with breast cancer.

Dr. Piccart on Metagene Prognostic Signatures

March 27th 2013

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the development of metagene prognostic signatures for patients with breast cancer.

Dr. Mark Pegram Discusses Earlier Treatment With T-DM1

March 26th 2013

Mark D. Pegram, MD, from the Stanford Cancer Institute, describes research into the antibody-drug conjugate T-DM1, following its FDA approval in February as a treatment for HER2-positive metastatic breast cancer.

NEXT PAGE
PREVIOUS PAGE